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Respiratory syncytial virus infection of primary human mast
cells induces the selective production of type I interferons,
CXCL10, and CCL4
AyhamAl-Afif, MSc,a* Raidan Alyazidi, MD,a,c,e* Sharon A. Oldford, PhD,a Yan Y. Huang, PhD,a,c Christine A. King, PhD,a§
Nico Marr, PhD,d Ian D. Haidl, PhD,a Robert Anderson, PhD,a,c,d and Jean S. Marshall, PhDa,b Halifax, Nova Scotia,
Canada, and Jeddah, Saudi ArabiaBackground: Respiratory syncytial virus (RSV) causes severe
respiratory tract infections, which might have a role in the
development of airway hyperreactivity. Mast cells are important
effector cells in allergy, with sentinel cell roles in host defense.
However, the role of mast cells in response to RSV infection is
unknown.
Objective: Human mast cell responses to RSV were investigated
with a view to better understanding the role of mast cells in
RSV-induced disease.
Methods: Human cord blood–derived mast cells and the HMC-1
mast cell line were exposed to RSVor UV-inactivated RSV. Viral
gene and protein expression were evaluated by using PCR and
flow cytometry. The expression of interferon-stimulated genes
and selected mediators were evaluated by using quantitative
PCR and ELISA.
Results: Human mast cells expressed multiple RSV genes after
exposure to RSV, and a small percentage of mast cells supported
RSV antigen protein expression. RSV induced mast cells to
upregulate production of chemokines, including CCL4, CCL5,
and CXCL10, as well as type I interferons, and interferon-
stimulated gene expression. However, production of the
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1346induced. Antibody blockade of the type I interferon receptor on
human cord blood–derived mast cells reduced the RSV-
mediated induction of CXCL10 and CCL4 but not CCL5.
Leukotriene C4 production by mast cells was not enhanced by
exposure to RSV.
Conclusion: Despite low levels of infection, human mast cells
produce multiple chemokines in response to RSV through
mechanisms that include responses to type I interferons. Such
mast cell responses might enhance effector cell recruitment
during RSV-induced disease. (J Allergy Clin Immunol
2015;136:1346-54.)
Key words: Mast cells, viral infection, innate immunity, respiratory
infection, chemokines, interferons, respiratory syncytial virus
Respiratory syncytial virus (RSV) is a pneumovirus
belonging to the Paramyxoviridae family with a nonsegmented,
negative-sense, single-stranded RNAgenome.1 RSVinfection is a
particular hazard to young children, the elderly, and immunocom-
promised patients. It is the leading cause of bronchiolitis and
pneumonia in children and hospitalization of infants worldwide.
RSV is also a major contributor to child mortality in developing
countries.2-5 There is still no effective vaccine for RSV, and rein-
fection with RSV is common.5,6 RSV infects mainly the respira-
tory epithelium, although restricted replication in human and
mouse alveolar macrophages,7 myeloid dendritic cells (DCs),
and plasmacytoid dendritic cells (pDC) has been reported,8-10 re-
sulting in functional changes.11,12 RSV-associated pathology is
characterized by an early neutrophil infiltrate of the peribronchial
areas and a mononuclear infiltrate in the interstitium of the lung
consisting of monocytes, double-negative CD31 T cells, and
CD81 T cells.13 There are also reports of eosinophil degranula-
tion in patients with severe disease.14,15 Initial TH2 skewing is
associated with prior experimental immunization16 or occurs
following neonatal infection of mice.13 Effective immunity to
RSV is thought to be regulated by a number of mechanisms,
including the nature of the primary responding effector cells,
the subsequent inflammatory cascade, and the ability of RSV to
subvert the function of professional antigen-presenting cells.
It is likely that immune sentinel cells in the airways, including
mast cells, play a role in the immune response to RSV. Mast cells
are immune effector cells best known for their role in acute allergy
and asthma.17 They are particularly prevalent within the skin,
gastrointestinal tract, and airways and are strategically located in
the perivasculature and the interstitium of the human lung. Mast
cells play a sentinel role in protecting the body from pathogens,
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parasite infection.18 The ability of mast cells to contribute to host
defense includes the recruitment of effector cells through cyto-
kine and chemokine production19-22 and the initiation of acquired
immunity through mobilization of DC responses.23-26 The ability
of mast cells to contribute to host defense against viral infection is
less well defined. However, mast cells can be infected by a num-
ber of viruses, including HIV, hantavirus, reovirus, dengue virus,
and influenza Avirus, and have been shown to selectively produce
mediators that activate vascular endothelium and recruit immune
effector cells.27-31
The nature of virus-inducedmediator production bymast cells is
dependent on the type of stimulation. For example, reovirus
infection of human mast cells leads to production of substantial
amounts of CXCL8, which enhances the migration of both human
neutrophils and natural killer (NK) cells.21 Through a
distinct mechanism, involving CCL3, CCL4, and CCL5,
reovirus-infected mast cells will recruit CD561 T cells.22 In
contrast, human mast cells infected by low doses of dengue virus
in the presence of subneutralizing concentrations of anti-dengue
antibodies produce little CXCL8 but have enhanced CCL4,
CCL5, and CXCL10 responses that could be associated with
T-cell subset recruitment.28 The effect of RSV on human mast
cell mediator production is of particular interest given the
suggested links between severeRSV-induced disease and the devel-
opment of childhood wheeze.32 Very few studies have investigated
the role of mast cells in the pathogenesis of RSV-induced disease.
However, bronchoalveolar lavage samples obtained from infants
hospitalized with RSV had higher levels of mast cell tryptase,33
which are indicative of mast cell degranulation. Furthermore, in-
fants with RSV-induced bronchiolitis had higher levels of urinary
9a,11b–prostaglandin F2, a marker of mast cell lipid mediator pro-
duction.34 Studies using guinea pig and ratmodels of RSVinfection
found an increased number of mast cells in lung tissue samples of
animals infectedwith the virus comparedwith control animals.35,36
Mast cells are amajor source ofmediators associatedwith broncho-
constriction, such as leukotriene C4 (LTC4),
18 and can also produce
other mediators found to be increased in the sputum and lavage
fluid of patients with RSV infections.15,18,32,37-39 These findings
suggest that mast cell responses to RSV can contribute to the path-
ogenesis of the disease.
In the current study the ability of RSV to infect primary cultured
human mast cells and to induce the production of inflammatory
mediators was investigated. RSV treatment ofmast cells led to viral
gene transcription and upregulation of interferon response genes
and selective mast cell type I interferon and chemokine responses,
with important implications for early antiviral responses.METHODS
Cell lines
HMC-1 and KU812 cells were grown in Iscove modified Dulbecco
medium (Invitrogen, Burlington, Ontario, Canada) supplemented with 10%
FBS (Medicorp, Montreal, Quebec, Canada), 1% L-glutamine (Thermo Fisher
Scientific, Nepean, Ontario, Canada), 100 U/mL penicillin G, and 100 mg/mL
streptomycin (Invitrogen).
Primary mast cells
Human cord blood–derived mast cells (CBMCs) were derived from
umbilical cord blood obtained with permission provided by the Izaak Walter
Killam Health Centre research ethics board (Halifax, Nova Scotia, Canada)
and cultured according to adaptations of the methods of Saito et al40 and
Radinger et al41; they were at least 95% pure as assessed by CD117 staining.
Briefly, mononuclear cells from cord blood were cultured in the presence of
100 ng/mL stem cell factor for 6-12 weeks with weekly changes in media
and the long lived mast cells that became predominant in these cultures
over time were used for experiments. In some cases CBMC cultures were
further sorted with a FACSAria II cell sorter (BDBiosciences, San Jose, Calif)
to isolate CD117hi maturemast cells. Before activation, CBMCswere cultured
overnight in medium devoid of prostaglandin E2 and with 10 ng/mL stem cell
factor. Mast cells produced in this way were on average (n5 4) 96.54% pos-
itive for CD117 (c-kit), 99.26% positive for mast cell tryptase, and less than
0.2% positive for a variety of other lineage markers including CD3, CD19,
CD56, CD11b, CD56, CD86, CD163 and CD209. Previous studies have
demonstrated that these types of mast cells express little TLR3 or TLR4 at
the protein level, without further cytokine treatments.42RSV propagation and treatment
RSV (Long strain) was propagated in HEp-2 cells in RPMI-1640 medium
containing 2.5% heat-inactivated FBS and then harvested when infected
cultures showed 80% to 90% cytopathic effect. The HEp-2 cells were lysed in
RNAse-free water, returned to physiologic osmolality with PBS (103,
Thermo Fisher Scientific), and finally centrifuged at 2095g for 10 minutes.
This inoculum routinely contained approximately 1 3 107 plaque-forming
units/mL. Where specified, RSV was pretreated with palivizumab (Abbot,
Saint-Laurent, Quebec, Canada) or pooled human IgG as a control at 10 mg/
mL for 30 minutes at 48C before addition to cells.Inoculation conditions
CBMCs or HMC-1 cells were inoculated with RSV, RSV pretreated with
palivizumab or human IgG, UV-inactivated RSV, or a medium control for 90
minutes at 48C. Mast cells were inoculated at a multiplicity of infection
(MOI) of 3 to 4 unless otherwise specified. Cells were washed and either
analyzed at this time point as a control for experiments assessing mast cell
infection or incubated at 378C in RPMI-1640 with 2.5% FCS (containing 10
ng/mL stem cell factor for CBMCs) and soybean trypsin inhibitor (Sigma-
Aldrich, St Louis, Mo) at 100 mg/mL, the latter being included to reduce the
proteolytic degradation of mast cell products. A peptidase inhibitor, acivicin
(Sigma-Aldrich), was included at 0.5 mmol/L in experiments in which LTC4
levels were measured. CBMCs were incubated at an initial concentration of
13 106 cells/mL, HMC-1 cells at 0.53 106 cells/mL. By the 24-hour time
point, because the HMC-1 cells have a doubling time of 24 hours in culture
and the mature CBMC are no longer dividing, both cell types were at a
similar concentration. Where indicated, CBMCs were incubated in the pres-
ence of an anti–IFN-a/b receptor antibody (MMHR-2 clone; Calbiotech,
Spring Valley, Calif) at a concentration of 5 mg/mL or an isotype control.
After incubation, cells, supernatants, and cell lysates were harvested for
mediator analysis.
The effect of RSV-infectedCBMCsupernatants onRSVinfection of HEp-2
cells was performed with RSV infection as described above, using a dose
which infected close to 20% of the HEp-2 cells. Supernatants from matched
RSV- or mock-infected CBMC 24 hour cultures were added during adsorption
and maintained throughout the 24 hour post-infection HEp-2 culture.
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Aliquots of clarified virus or CBMC cell lysates from RSV-treated cells
were serially diluted and inoculated onto 80% to 90% confluent HEp-2 cell
monolayers. Plaque assays were performed as previously described.43,44
Fluorescence-activated cell sorting staining and
analysis
For CD117/c-Kit staining, CBMCs were incubated with allophycocyanin-
conjugated anti-human CD117 mAb or mouse IgG1 (eBioscience, San Diego,
Calif) at a concentration of 1mg/mL. For intracellular RSVantigen staining, cells
were fixed with 1% paraformaldehyde, permeabilized in 0.2% saponin (Sigma-
Aldrich), and incubated with biotin-conjugated goat anti-RSV serum (Meridian
Life Sciences,Memphis, Tenn) at 5mg/mL.Biotin-labeled goat IgG (Jackson Im-
munoResearch,West Grove, Pa) was used as a control. Cells were then incubated
with streptavidin-conjugated PE (eBioscience) and fixed in 1% paraformalde-
hyde. Sampleswere acquiredwith aFACSCalibur (BDBiosciences). Intracellular
RSVantigen expression was determined by using 0-hour readings (immediately
after RSV adsorption and washing) as a control, and data were analyzed with
FCS Express 3 software (Denovo Software, Los Angeles, Calif).
Quantitative PCR
Total RNA was extracted with the RNeasy Plus Mini Kit (Qiagen,
Mississauga, Ontario, Canada). Genomic DNA was depleted, and cDNA was
generated with the QuantiTect Reverse Transcription Kit (Qiagen). Commercial
primer pairs (Qiagen) for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), hypoxanthine phosphoribosyltransferase 1 (HPRT1), CCL4, CCL5,
CXCL10, IFNA1, IFNB, interferon-stimulated gene 56 (ISG56), and myxovirus
resistance gene 1 (MX1 [MxA]) were used to assess the relative expression of
genes. RSV-specific primers for NS1, N, and F (Sigma) were as described by
Boukhvalova et al.44 The QuantiFast SYBR Green PCR Kit (Qiagen) was used
to perform duplicate quantitative PCR (qPCR) reactions in the MX-3000P
QPCR System (Stratagene, La Jolla, Calif). Data were analyzed with MxPro
Software (Stratagene), and the fold induction of gene expression was calculated
by using the Pfaffl method,45 or when appropriate, they were normalized to
HPRT1 and GAPDH and expressed as 2 to the power of the difference between
the threshold cycles for amplification of the reference gene and target gene.
Mediator analysis
ELISAswere performed tomeasure the supernatant concentrations of human
CCL4 (R&D Systems, Minneapolis, Minn), CXCL10 (BD PharMingen), and
CCL11 (PeproTech, Rocky Hills, NJ). The CCL5 ELISA used a rabbit anti-
human CCL5 antibody (Endogen, Woburn, Mass) with a goat anti-human
secondary antibody (R&DSystems). LTC4 levels weremeasured according to a
modification of the protocol fromVolland et al.46 A commercial high-sensitivity
amplification system (Invitrogen) was used for all ELISAs. For detection of
IFN-a2 and IFN-b in supernatants and selected CXCL10measurements, Lumi-
nex assays were used (eBioscience and Bio-Rad Laboratories, Hercules, Calif).
Statistical analysis
HMC-1 cell line data were analyzed by using repeated-measures 1-way
ANOVA, followed by the Dunnett multiple comparison test. In experiments
with CBMCs, data were either log transformed and analyzed with the paired t
test or, for multiple comparisons, analyzed with repeated-measures 1-way
ANOVA, followed by the Sidak comparison for selected pairs. In some cases
(as stated), in view of nonnormal data distribution, data were directly analyzed
by using the Friedman test, followed by the Dunn selected pairs comparison.P
values of less than .05 were considered significant. All statistical analyses
were performed with Prism 6 software (GraphPad Software, La Jolla, Calif).
RESULTS
Human mast cells support RSV antigen expression
The intracellular expression of RSV proteins was quantified by
means of flow cytometry in CBMCs inoculated with RSV orUV-inactivated RSV or treated with a medium control to
investigate the effect of RSV exposure on human mast cells.
Maximum viral antigen expression was detected in response to
live but not UV-inactivated virus in a small proportion of CD117hi
cells (ie, mature mast cells) at 24 hours after infection (median,
0.7%; interquartile range, 0.5% to 1.2% in RSV-infected cells
vs 0% in UV-RSV treated cells; n5 12 donors; Fig 1, A). Similar
levels of viral protein expression were observed after 48 hours
(n5 3), but by 72 hours, no viral protein expression was detected.
CBMCs maintained similar viabilities in all groups. In addition,
the expression of 3 representative RSV genes, NS1, N, and F,
was detected by using qPCR at 24 hours in CBMCs exposed to
RSV (Fig 1, C). Pretreatment of RSV with palivizumab
reduced the percentage of cells expressing RSV antigen by
49% 6 14.9% (mean 6 SEM, n 5 8 donors).
The human mast cell line HMC-1 was inoculated with RSVat
increasingMOI levels (0.6-0.8, 1.5-2, 3-4, and 6-8), incubated for
24 hours, and stained to detect intracellular RSV antigen
expression to confirm that these responses were not limited to
CBMCs. There was increased RSV antigen expression by cells
treated with live RSV compared with those treated with
UV-inactivated RSV (P < .01; Fig 1, B) at higher MOI levels.
PCR analysis confirmed the expression of RSV genes after
HMC-1 infection (data not shown).
Plaque assays were performed to determine whether mast cells
were productively infected with RSV. CBMC cell lysates were
harvested from 5 different donors after 24 and 48 hours of RSV
infection and compared with RSV-infected HEp-2 stock in plaque
assays. No plaques were detected from RSV-inoculated CBMCs,
whereas plaques were observed from HEp-2 cells after 48 hours,
indicating that treatment of CBMCs with RSV does not lead to
substantial infectious virus formation.
The possibility that mast cell products acted directly to inhibit
the ability ofRSV to infect cellswas also examined experimentally.
The HEp-2 epithelial cell line was infected with RSV in the
presence or absence of supernatants from CBMC that had been
infected with RSV for 24 hours or mock-infected mast cell
supernatants. Our results demonstrate that CBMC supernatants
had no significant direct impact on the ability of RSV to infect these
epithelial cells under our experimental conditions. Specifically,
mock-infected HEp-2 cells were <1% RSVantigen positive, RSV
infected HEp-2 cells were a mean of 19.7 6 0.5% RSV positive,
HEp-2 cells infectedwithRSVin the presence of supernatants from
mock-infected CBMC were 21.7 6 5.6% positive, while HEp-2
cells infected with RSV in the presence of supernatants from RSV
infected CBMC were 18.76 3.7% positive (n5 3).CBMCs produce selective chemokines in response
to RSV
CCL4, CCL5, CCL11, CXCL10, and CXCL8 levels are
increased in nasal and bronchoalveolar lavage samples of children
hospitalized with severe RSV-induced bronchioli-
tis.15,32,38,39,47-49 Mast cell production of these cytokines in
response to RSV was examined. CBMCs were stimulated for
24 hours with medium, RSV, UV-inactivated RSV, or RSV pre-
treated with either palivizumab or human IgG control. Protein
levels of chemokines were quantified in cell-free supernatants
24 and 48 hours after RSV treatment. CBMCs inoculated with
RSV produced significantly higher amounts of CXCL10
and CCL4 at 24 hours compared with medium control–treated
FIG 1. RSV infection of primary human mast cells (CBMCs) and HMC-1 cells. A, Intracellular RSV antigen
expression in CBMCs (representative of n 5 13 donors) and in HMC-1 cells 24 hours after infection.
B, RSV antigen expression 24 hours after infection in HMC-1 cells at different MOIs (n 5 4, mean 6 SEM).
C, Induction of the RSV genes NS1, N, and F in RSV-infected CBMCs compared with that seen in
mock-treated control cells 24 hours after infection (n 5 7 CBMC donors, mean 6 SEM). *P < .05,
**P < .01, and ****P < .0001.
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respectively) cells (Fig 2, A). This response was highly selective,
with neither CCL11 (Fig 2, A) nor CXCL8 being produced at sig-
nificant levels (data not shown). The amounts of CCL5 produced
were much lower than those of CCL4 and CXCL10 in response to
RSV. However, CCL5 production from CBMCs was still
increased in response to RSV compared with medium control–
or UV-inactivated virus–treated cells (P < .05; Fig 2, A).
Chemokine levels detected in CBMC supernatants at 48 hours
were diminished compared with those at the 24-hour time point,
but a similar trend in chemokine production was observed. It is
possible that the chemokines might have been degraded by
mast cell proteases. RSV pretreatment with palivizumab showed
a trend toward lower CXCL10, CCL4, and CCL5 responses
compared with those in infected cells or control IgG-treated
RSV-infected cells (Fig 2, A).
A time-course analysis for selected chemokines was performed
to delineate the kinetics of the chemokine response by CBMCs.
CXCL10 and CCL4 levels started to increase sharply after 6 hours
and continued to increase until 24 hours (data not shown). In
addition, induction of chemokine mRNA relative to that seen in
control-treated cells was measured by using qPCR for CXCL10,
CCL4, and CCL5. Levels of these mRNAs were significantly
increased for the RSV group compared with the UV-RSV group
(P < .01; Fig 2, B).To further confirm these results, HMC-1 cells were treated with
various MOIs of RSV or controls, and the supernatant levels of
CXCL10, CCL4, and CCL5 at 24 hours after infection were
quantified by using ELISA. HMC-1 cells produced CCL4, CCL5,
and CXCL10 in a dose-dependent manner after RSV inoculation
when compared with levels seen in control cells (Fig 3).CBMCs do not produce LTC4 in response to RSV
Mast cells produced substantial amounts of LTC4 after activa-
tion with calcium ionophore at 30minutes (median, 8,677 pg/mL;
interquartile range, 4,682-17,265; n 5 4 donors). However, no
significant LTC4 response was observed by CBMCs from the
same donors treated with RSV either at 30 minutes or later time
points (4-6 hours, 12 hours, and 18-24 hours).RSV-induced mast cell production of selected
chemokines depends on early type I interferons
Type I interferons mediate their antiviral effector actions
through the activation of a group of interferon response genes,
such as ISG56 (IFIT1) andMX1 (MxA).50 To elucidate a potential
mechanism for regulation of chemokine production in mast cells
exposed to RSV, we first investigated the type I interferon
responses in CBMCs 24 hours after infection. There was higher
FIG 2. Chemokine production from CBMCs 24 and 48 hours after RSV
infection. A, Levels of chemokines 24 hours and 48 hours after RSV
=
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mRNA (P < .01) in CBMCs inoculated with RSV than in
UV-RSV–treated cells (Fig 4, A). Supernatants from CBMCs
treated with RSV had consistently higher levels of IFN-a2 (P <
.05) and IFN-b compared with medium-treated or UV-
inactivated virus-treated cells (Fig 4, B). Mast cells did not
produce IFN-g after RSV stimulation at 24 or 48 hours (Fig 4,C).
To evaluate the role of type I interferon responses bymast cells in
their chemokine profile after RSVexposure, we blocked the type I
interferon receptor after virus adsorption and then collected
supernatants for chemokine assays. The efficacy of type I interferon
receptor blockadewas confirmed in the KU812 cell line stimulated
with IFN-a2 (see Fig E1 in this article’s OnlineRepository atwww.
jacionline.org). CBMCs activated with RSV produced lower
CXCL10 and CCL4 protein levels when treated with type I inter-
feron blocking antibody compared with when treated with an iso-
type control antibody (P < .01, Fig 5). In contrast, CCL5
production by mast cells in response to RSV was not affected
(Fig 5). No significant inhibitory effect on viral antigen expression
was noted with type I interferon receptor blockade.DISCUSSION
This study demonstrates that human mast cells respond with
substantial and selective type I interferon and chemokine pro-
duction after direct exposure to RSV, despite limited classical
viral infection. These findings implicate mast cells in early
monocyte and T-cell recruitment after RSV infection. Although
RSV genes were transcribed and a low level of RSV antigen
expression was detected in CBMCs, there was no detectable
production ofmature progeny virus frommast cells. This suggests
that mast cells are capable of mobilizing aspects of an antiviral
response without significantly furthering viral propagation.
The production of mediators after RSV infection of mast cells
was highly selective and dependent on exposure to active virus.
This suggests that either fusion,51 uptake of active virus, or some
degree of viral activity was required to directly or indirectly
initiate these responses. There are several mechanisms whereby
viral infection can induce expression of interferons and chemo-
kines. Many of these rely on direct interaction of viral RNA or
DNAwith sensors within the cell, such as retinoic acid–inducible
gene 1, melanoma differentiation-associated protein 5, and
Toll-like receptors 3, 7, and 9.52 UV-inactivated virus was not
an effective inducer of mediator production from mast cells,
suggesting that viral binding alone is not sufficient to induce
the observed mediator responses.
The large amount of chemokines produced by humanmast cells
after limited RSV infection, together with the requirement of
active virus for chemokine induction, suggests an indirect
chemokine induction mechanism. We demonstrate not only that
RSV infection induces mast cells to produce type I interferons
(Fig 4) but also that type I interferon receptor blockade onCBMCsinfection with and without blockade of infection with palivizumab (Pal; for
CXCL10 24 and 48 hours, n 5 9; CCL4 24 hours, n 5 12; CCL4 48 hours,
n 5 5; CCL5 24 hours, n 5 10; CCL5 48 hours, n 5 4; CCL11 n 5 2;
mean 6 SEM). B, CXCL10, CCL4, and CCL5 gene upregulation in
RSV-treated CBMCs and UV-inactivated virus–treated CBMCs compared
with that seen in medium-treated CBMCs 24 hours after infection (n 5 5
donors, mean 6 SEM). *P < .05 and **P < .01.
FIG 3. Dose-dependent chemokine production fromHMC-1 cells at 24 hours
after infection with varying MOIs of RSV (n5 4, mean 6 SEM). *P < .05 and
**P < .01.
FIG 4. Type I and II interferon responses in CBMCs after infection with RSV.
A, Fold induction of some type I interferons and interferon-stimulated
genes at 24 hours in UV-RSV– and RSV-treated CBMCs relative to values
seen in medium-treated CBMCs (n 5 6 donors, mean 6 SEM). B, IFN-a2
and IFN-b secreted from CBMCs 24 hours after infection. C, IFN-g at 24
and 48 hours after CBMC infection with RSV (n 5 5 donors, mean 6 SEM
in Fig 4, B and C). *P < .05 and **P < .01. ns, Not significant.
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and CCL4 but not CCL5 (Fig 5). These results are consistent with
a model in which RSV infection of a subset of mast cells or an
early mast cell response to signals associated with viral protein
FIG 5. Effect of blocking type I interferon receptor on chemokine
production by CBMCs during RSV infection at 24 hours (n 5 7 donors,
mean 6 SEM). *P < .05 and **P < .01. ns, Not significant.
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then act on neighboring cells to induce selective CXCL10 andCCL4 production. Therefore, mast cells would contribute to an
early antiviral state in surrounding cells and to the recruitment
of antiviral effector cells, such as T cells, through both type I inter-
feron and chemokine production. These activities could be further
enhanced by interferons and other cytokine signals from the
neighboring epithelium.53 Our data suggest that the time course
of chemokine production from mast cells after RSV exposure
might be limited. By the 48-hour time point, there was a reduced
response to RSV, which might reflect the limited exposure of cells
to both new virus particles and mast cell–derived type I inter-
ferons. These results are in keeping with our observations that
no progeny virus is observed from mast cells. It is possible that
degradation of chemokines frommast cells by mast cell proteases
might contribute to reduced chemokine detection at later time
points. Because RSV is recognized to be a labile virus in cell cul-
ture and cells are washed after viral adsorption, there is little free
virus available from the initial inoculum to provide a source for
ongoing mast cell infection. This was confirmed by our plaque
assay studies in which no infectious virus was observed from
RSV-treated mast cell cultures.
Notably, the profile of chemokines produced by mast cells
exposed to RSV overlaps considerably with that reported from
virally infected pDCs, which have the capacity to induce the
recruitment of T and NK cells.54 Because mast cells, unlike pDCs,
are resident in the human airways in substantial numbers, theymight
be particularly important for the initial chemokine response to infec-
tion. In addition, activated mast cells have also been shown to
contribute to DC recruitment to inflammatory sites55-58 and there-
fore could contribute to a coordinated DC and mast cell response
to infection. CXCL10 has the ability to recruit macrophages and
DCs and augment CD81 T-cell efficacy in vivo in mice and enhance
type I interferon production from DCs in vitro.59 CCL4 is also
important in T-cell recruitment to inflamed sites and regulates the
migration of monocytes, DCs, and NK cells.60,61 CCL4 and
CCL5 induce IL-12 production from DCs and have been shown
to enhance a TH1 response in a parasite model.
62
The ability of RSV to infect human mast cells has previously
been examined by using the HMC-1 cell line. This study
concluded that mast cells could not be infected by RSV and
only responded to RSV indirectly when cocultured with infected
airway epithelial cells.63 Our data clearly document viral gene
expression and RSV protein expression in both CBMC and the
HMC-1 cell line (Fig 1). The large amount of cellular activity
devoted to cell division and growth, as well as the range of stages
of cell cycle that are found within the HMC-1 cells might
contribute to their reduced chemokine response, compared with
CBMC. Their relatively immature mast cell phenotype may also
limit their chemokine responses, directly or indirectly. HMC-1
cells are certainly not a perfectmodel for human in vivomast cells.
However, the HMC-1 data we provide does demonstrate that even
100% pure mast cells show a similar level of infection and range
of chemokine responses as CBMC following RSV treatment. In
keeping with our findings, RSV treatment of peripheral blood
derived mast cells has also previously been reported to induce a
type I IFN response.64 Taken together these findings suggest
that multiple sources of human mast cells might share the ability
to enhance local antiviral immunity in response to RSV.
That we could not detect mature RSV progeny production in
infected CBMC, could be due to the low levels of infection or
due to nonproductive infection of mast cells as documented in
influenza infection of mast cells.65 In either case the primary
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likely to enhance the recruitment of effector cells throughmediator
production, including type I interferons, CXCL10, and CCL4. The
lack of any evidence of virus-induced LTC4 production suggests
little role for mast cells as a direct source of this mediator inducing
bronchoconstriction; however, additional inflammatory factors
could help promote mast cell activation and cysteinyl leukotriene
production in vivo. Notably, in severe bovine RSV infection of
calves considerable mast cell degranulation has been noted.66 It
is not clear if this is a direct consequence of RSV infection or a
result of other aspects of the inflammatory pathology in this disease.
In a separate study by Kimman et al,67 mast cell degranulation was
also observed in infected calves. However, complement activation
and antiviral antibodieswere also consistently observed. Therefore,
both direct antibody mediated mechanisms and complement
mediated pathways could contribute to the observed changes in
mast cell granulation status. These studies of later stage disease
suggest that the role of the mast cell might not be limited to the
very early response to RSV infection, in the absence of specific
antibody that we have examined experimentally.
Overall, our study suggests that, despite evidence of only limited
RSV infection, human mast cells can support viral gene expression
and have a role in RSV disease pathology and immunity through
type I interferon and chemokine production. The ability of mast
cells to produce significant levels of CCL4, CCL5, and CXCL10,
which are associated with T-cell, NKT cell, and monocyte
recruitment, but not CCL11 or CXCL8, which have major roles
in eosinophil and neutrophil recruitment, suggests a role for mast
cells in RSV control rather than damaging bronchiolitis. The long-
lived resident nature of mast cells in the respiratory tract enables
them to respond as sentinel cells very early to RSV infection and
orchestrate the ensuing immune response. Through manipulation
of human mast cell response to viruses, such as RSV, and to type I
interferons, there might be opportunities to locally enhance
effective early antiviral immunity and limit damaging inflamma-
tion associated with RSV infection.
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Key Messages
d Despite limited RSV infection of human mast cells, RSV
treatment results in substantial and selective type I inter-
feron and chemokine responses (CXCL10, CCL4, and
CCL5).
d RSV induction of CXCL10 and CCL4, but not CCL5, in
human mast cells is dependent on the autocrine or para-
crine action of type I interferons.
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FIG E1. Induction of the interferon-stimulated gene ISG56 by IFN-a2 at 24
hours with and without antibody blockade of the type I interferon receptor
in KU812 cells to confirm functional efficiency of receptor blockade (n 5 4,
mean 6 SEM). *P < .05 and ***P < .001.
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